ArticleInternational dental journal2026
The Burden and Risk Factors of Head and Neck Cancers in G20 Countries, 1990-2023.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancers (HNC) rank as the sixth most common cancers globally, yet comprehensive epidemiology among the Group of Twenty (G20) nations is lacking.
methodsThis secondary analysis of Global Burden of Disease 2023 data systematically assessed the spatiotemporal trends, population disparities and risk-attributable burden (excluding viral factors) of age-standardised rates for HNC across G20 countries. Future trends were forecast using an autoregressive integrated moving average (ARIMA) model.
resultsIn 2023, lip and oral cavity cancer (LOCC) presented the highest burden among HNC subtypes across the G20, with an age-standardised incidence rate (ASIR) of 4.52 per 100,000, corresponding to 283,441 new cases. India carried the highest burden of LOCC, China that of nasopharyngeal carcinoma (NPC) and France that of laryngeal and other pharyngeal cancers (LC/OPC). From 1990 to 2023, LOCC and OPC incidence rose overall while LC and NPC declined. South Korea showed the fastest NPC increase, while the United Kingdom had the steepest rise in LOCC/OPC. China recorded the most significant reductions in NPC age-standardised mortality and disability-adjusted life year rates (ASMR and ASDR), whereas France showed the sharpest decline in LOCC/OPC. Indonesia was the sole country with consistent increases across all subtypes. Although males are predominantly affected, female incidence was higher for NPC in the United Kingdom and for LOCC/OPC in Saudi Arabia. The HNC burden concentrates in elderly populations, with tobacco and alcohol as leading risk factors, though their contributions vary by country and sex. Projections to 2038 indicate likely increases in OPC and NPC incidence, with LOCC remaining the predominant contributor.
conclusionMarked regional, sex and age disparities in HNC burden and risk factors exist across G20 nations. CLINICAL RELEVANCE: These disparities provide an evidence base to mobilise health-development assistance and to design precise, differentiated transnational control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.